Assenagon Asset Management
EGRX

Assenagon Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Assenagon Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-183,592
Closed -$685K – 1474
2024
Q3 		$685K Sell
183,592
-1,745
-0.9% -$8.32K ﹤0.01% 1191
2024
Q2 		$1.04M Hold
185,337
– – ﹤0.01% 1090
2024
Q1 		$971K Sell
185,337
-32,331
-15% -$177K ﹤0.01% 1065
2023
Q4 		$1.14M Hold
217,668
– – ﹤0.01% 1067
2023
Q3 		$3.43M Buy
217,668
+86,917
+66% +$1.56M 0.01% 677
2023
Q2 		$2.54M Sell
130,751
-43,909
-25% -$1.04M 0.01% 686
2023
Q1 		$4.96M Buy
174,660
+62,408
+56% +$1.85M 0.02% 575
2022
Q4 		$3.28M Buy
112,252
+34,695
+45% +$1.1M 0.01% 648
2022
Q3 		$2.05M Sell
77,557
-5,707
-7% -$209K 0.01% 709
2022
Q2 		$3.7M Sell
83,264
-4,465
-5% -$205K 0.01% 634
2022
Q1 		$4.34M Buy
87,729
+35,649
+68% +$1.71M 0.01% 560
2021
Q4 		$2.65M Buy
52,080
+9,037
+21% +$468K 0.01% 719
2021
Q3 		$2.4M Buy
+43,043
New +$2.12M 0.01% 639

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Assenagon Asset Management's EGRX Position: Q4 2024 in Review

Assenagon Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 183,592 shares — an estimated $685K sold.

Assenagon Asset Management first reported a position in EGRX in Q3 2021 and held it in 13 quarters. The position peaked at $4.96M in Q1 2023. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Assenagon Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Assenagon Asset Management sold 183,592 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $685K.
  • Assenagon Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2021 and held it in 13 quarters.
  • Assenagon Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $4.96M in Q1 2023.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Assenagon Asset Management's 13F filing for Q4 2024, filed 14 Jan 2025.